- |||||||||| Kineret (anakinra) / SOBI
Enrollment change, Trial completion date, Trial termination, CAR T-Cell Therapy, Metastases: A Study of CART-PSMA-TGF?RDN in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 13, 2023
P1, N=16, Terminated,
Recruiting --> Active, not recruiting N=50 --> 16 | Trial completion date: Nov 2036 --> Nov 2022 | Active, not recruiting --> Terminated; Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.
- |||||||||| CART-PSMA- TGFβRDN cells / Tmunity Therap, TmPSMA-02 / Tmunity Therap
Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_672;
P1
Background We previously reported preliminary safety and efficacy results from a multi-center Phase 1 trial of CART-PSMA-TGFβRDN T-cells (TmPSMA-01; NCT04227275 ) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)...Knowledge gained from these studies supported the development of a next-generation PSMA-targeting CAR, TmPSMA-02, to improve safety while maintaining anti-tumor activity and will be explored in a multi-center, Ph1/2 trial for pts with mCRPC...The clinical study protocol and the informed consent form (ICF) were both reviewed and approved by the properly chartered IRBs and Independent Ethics Committee before the study commenced. Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study.
- |||||||||| CART-PSMA- TGF?RDN cells / Gilead
Enrollment open, Trial completion date, Trial primary completion date, Metastases: CART-PSMA-TGF?RDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Mar 21, 2022
P1, N=19, Recruiting,
Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study. Active, not recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2038 | Trial primary completion date: Sep 2022 --> Sep 2038
- |||||||||| Kineret (anakinra) / SOBI, CART-PSMA- TGFβRDN cells / Tmunity Therap
Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC. (In-Person & On Demand | Level 1, West Hall - E7) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_326;
P1
The exact mechanisms driving the severe immune-mediated toxicities in this study are currently unclear. While this study has been closed to further enrollment, ongoing research efforts are aimed at exploring patient specific factors, tumor microenvironment factors, and the PSMA-CART construct (including both functional components and armored modules) to design future constructs of PSMA-CART that will enhance the efficacy/safety profile and allow for continued study of this novel therapy in the clinic.
- |||||||||| CART-PSMA- TGF?RDN cells / Gilead
Trial completion date, Trial primary completion date, Metastases: CART-PSMA-TGF?RDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 14, 2021
P1, N=18, Active, not recruiting,
While this study has been closed to further enrollment, ongoing research efforts are aimed at exploring patient specific factors, tumor microenvironment factors, and the PSMA-CART construct (including both functional components and armored modules) to design future constructs of PSMA-CART that will enhance the efficacy/safety profile and allow for continued study of this novel therapy in the clinic. Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- |||||||||| Kineret (anakinra) / SOBI
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Metastases: A Study of CART-PSMA-TGF?RDN in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - May 26, 2020
P1, N=50, Recruiting,
Trial primary completion date: Sep 2020 --> Sep 2021 Active, not recruiting --> Recruiting | N=18 --> 50 | Trial completion date: Apr 2022 --> Nov 2036 | Trial primary completion date: Nov 2020 --> Nov 2022
|
